Purpose: Mammalian target of rapamycin (mTOR) is a promising target in small cell lung
cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in …

7005 Background: Temsirolimus (CCI-779), an ester of sirolimus, is an inhibitor of mTOR,
shown to inhibit tumor cell proliferation in non-clinical models. Standard chemotherapy …

Hypothesis To study the progression-free survival (PFS) and toxicity with 25-or 250-mg
doses of temsirolimus (CCI-779) after induction chemotherapy in patients with extensive …

Background This exploratory single-arm phase II study evaluated the efficacy and safety of
RRx-001 followed by reintroduction of platinum plus etoposide in patients with previously …

Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are
active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study …

Background In preclinical models, the proteasome inhibitor bortezomib (PS-341) inhibits the
growth of small cell lung cancer (SCLC) by inhibiting the antiapoptotic Bcl-2 signaling …

Background The aim of this prospective, pilot, single‐arm phase II trial was to evaluate the
safety and efficacy of anlotinib combined with etoposide and platinum‐based regimens in …

Background: In this report we investigated the combination of epidermal growth factor
receptor (EGFR) and mammalian target of rapamycin (mTOR) pathway inhibition as a …

7564 Background: Scientific evidence supports the concept that the growth of solid tumors,
including SCLC, is dependent on angiogenesis. Bevacizumab, a humanized monoclonal …

Purpose Considering promising results in phase II studies, a randomized phase III trial was
designed to assess the efficacy of adding bevacizumab to first-line cisplatin plus etoposide …